152 related articles for article (PubMed ID: 10718212)
1. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of MDM2 protein in intrahepatic cholangiocarcinoma: relationship with p53 overexpression, Ki-67 labeling, and clinicopathological features.
Horie S; Endo K; Kawasaki H; Terada T
Virchows Arch; 2000 Jul; 437(1):25-30. PubMed ID: 10963376
[TBL] [Abstract][Full Text] [Related]
3. MDM2 Amplification in Intrahepatic Cholangiocarcinomas: Its Relationship With Large-Duct Type Morphology and Uncommon KRAS Mutations.
Kim SJ; Akita M; Sung YN; Fujikura K; Lee JH; Hwang S; Yu E; Otani K; Hong SM; Zen Y
Am J Surg Pathol; 2018 Apr; 42(4):512-521. PubMed ID: 29309301
[TBL] [Abstract][Full Text] [Related]
4. Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma.
Furubo S; Harada K; Shimonishi T; Katayanagi K; Tsui W; Nakanuma Y
Histopathology; 1999 Sep; 35(3):230-40. PubMed ID: 10469215
[TBL] [Abstract][Full Text] [Related]
5. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
Molina P; Pellín A; Navarro S; Boix J; Carda C; Llombart-Bosch A
Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
[TBL] [Abstract][Full Text] [Related]
6. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
7. Microsatellite instability and alternative genetic pathway in intrahepatic cholangiocarcinoma.
Momoi H; Itoh T; Nozaki Y; Arima Y; Okabe H; Satoh S; Toda Y; Sakai E; Nakagawara K; Flemming P; Yamamoto M; Shimahara Y; Yamaoka Y; Fukumoto M
J Hepatol; 2001 Aug; 35(2):235-44. PubMed ID: 11580146
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the p16INK4, p14ARF, p15, TP53, and MDM2 genes and their prognostic implications in osteosarcoma and Ewing sarcoma.
Tsuchiya T; Sekine K; Hinohara S; Namiki T; Nobori T; Kaneko Y
Cancer Genet Cytogenet; 2000 Jul; 120(2):91-8. PubMed ID: 10942797
[TBL] [Abstract][Full Text] [Related]
9. Expression of G1-S modulators (p53, p16, p27, cyclin D1, Rb) and Smad4/Dpc4 in intrahepatic cholangiocarcinoma.
Kang YK; Kim WH; Jang JJ
Hum Pathol; 2002 Sep; 33(9):877-83. PubMed ID: 12378511
[TBL] [Abstract][Full Text] [Related]
10. Correlation of p53 gene mutation and expression of P53 protein in cholangiocarcinoma.
Liu XF; Zhang H; Zhu SG; Zhou XT; Su HL; Xu Z; Li SJ
World J Gastroenterol; 2006 Aug; 12(29):4706-9. PubMed ID: 16937443
[TBL] [Abstract][Full Text] [Related]
11. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas.
Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH
Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320
[TBL] [Abstract][Full Text] [Related]
12. Mutation inactivation of Nijmegen breakage syndrome gene (NBS1) in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Wang Y; Hong Y; Li M; Long J; Zhao YP; Zhang JX; Li Q; You H; Tong WM; Jia JD; Huang J
PLoS One; 2013; 8(12):e82426. PubMed ID: 24349281
[TBL] [Abstract][Full Text] [Related]
13. Intraductal papillary neoplasms of the bile duct: stepwise progression to carcinoma involves common molecular pathways.
Schlitter AM; Born D; Bettstetter M; Specht K; Kim-Fuchs C; Riener MO; Jeliazkova P; Sipos B; Siveke JT; Terris B; Zen Y; Schuster T; Höfler H; Perren A; Klöppel G; Esposito I
Mod Pathol; 2014 Jan; 27(1):73-86. PubMed ID: 23828315
[TBL] [Abstract][Full Text] [Related]
14. p53 gene mutations and expression of p53 and mdm2 proteins in invasive breast carcinoma. A comparative analysis with clinico-pathological factors.
Günther T; Schneider-Stock R; Rys J; Niezabitowski A; Roessner A
J Cancer Res Clin Oncol; 1997; 123(7):388-94. PubMed ID: 9260591
[TBL] [Abstract][Full Text] [Related]
15. Impact of alterations affecting the p53 pathway in bladder cancer on clinical outcome, assessed by conventional and array-based methods.
Lu ML; Wikman F; Orntoft TF; Charytonowicz E; Rabbani F; Zhang Z; Dalbagni G; Pohar KS; Yu G; Cordon-Cardo C
Clin Cancer Res; 2002 Jan; 8(1):171-9. PubMed ID: 11801555
[TBL] [Abstract][Full Text] [Related]
16. High throughput molecular profiling reveals differential mutation patterns in intrahepatic cholangiocarcinomas arising in chronic advanced liver diseases.
Jang S; Chun SM; Hong SM; Sung CO; Park H; Kang HJ; Kim KP; Lee YJ; Yu E
Mod Pathol; 2014 May; 27(5):731-9. PubMed ID: 24186137
[TBL] [Abstract][Full Text] [Related]
17. p53 Mutations in human cholangiocarcinoma: a review.
Khan SA; Thomas HC; Toledano MB; Cox IJ; Taylor-Robinson SD
Liver Int; 2005 Aug; 25(4):704-16. PubMed ID: 15998419
[TBL] [Abstract][Full Text] [Related]
18. Mutational spectrum and precision oncology for biliary tract carcinoma.
Lin J; Cao Y; Yang X; Li G; Shi Y; Wang D; Long J; Song Y; Mao J; Xie F; Bai Y; Zhang L; Yang X; Wan X; Wang A; Guan M; Zhao L; Hu K; Pan J; Huo L; Lu X; Mao Y; Sang X; Zhang H; Wang K; Wang X; Zhao H
Theranostics; 2021; 11(10):4585-4598. PubMed ID: 33754015
[No Abstract] [Full Text] [Related]
19. p53 Mutation and MDM2 amplification in inflammatory myofibroblastic tumours.
Yamamoto H; Oda Y; Saito T; Sakamoto A; Miyajima K; Tamiya S; Tsuneyoshi M
Histopathology; 2003 May; 42(5):431-9. PubMed ID: 12713619
[TBL] [Abstract][Full Text] [Related]
20. The early growth response gene EGR-1 behaves as a suppressor gene that is down-regulated independent of ARF/Mdm2 but not p53 alterations in fresh human gliomas.
Calogero A; Arcella A; De Gregorio G; Porcellini A; Mercola D; Liu C; Lombari V; Zani M; Giannini G; Gagliardi FM; Caruso R; Gulino A; Frati L; Ragona G
Clin Cancer Res; 2001 Sep; 7(9):2788-96. PubMed ID: 11555594
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]